Lancet Publishes SELECT Study of Biogen's Daclizumab HYP, Biogen Says ... Benzinga Today Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase 2b study designed to determine the efficacy ... Market opening: Biogen Idec up after positive MS drug study |
